Response to letter regarding article, "efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation"

Autoria(s): Wallentin,L; Lopes,RD; Hanna,M; Thomas,L; Hellkamp,A; Nepal,S; Hylek,EM; Al-Khatib,SM; Alexander,JH; Alings,M; Amerena,J; Ansell,J; Aylward,P; Bartunek,J; Commerford,P; De Caterina,R; Erol,C; Harjola,VP; Held,C; Horowitz,J; Huber,K; Husted,S; Keltai,M; Lanas,F; Lisheng,L; McMurray,JJ; Oh,BH; Rosenqvist,M; Ruzyllo,W; Steg,PG; Vinereanu,D; Xavier,D; Granger,CB
Data(s)

14/01/2014
Identificador

http://hdl.handle.net/10536/DRO/DU:30072854
Idioma(s)

eng
Publicador

Lippincott Williams & Wilkins
Relação

http://dro.deakin.edu.au/eserv/DU:30072854/amerena-responseto-2014.pdf

http://www.dx.doi.org/10.1161/CIRCULATIONAHA.113.005709

http://www.ncbi.nlm.nih.gov/pubmed/24421367
Direitos

2014, Lippincott Williams and Wilkins
Palavras-Chave #Science & Technology #Life Sciences & Biomedicine #Cardiac & Cardiovascular Systems #Peripheral Vascular Disease #Cardiovascular System & Cardiology #ARISTOTLE TRIAL
Tipo

Journal Article
Acesso ao item digital